Milestone Pharmaceuticals
Milestone is focused on advancing cardiac therapy by developing self-administered anti-arrhythmia treatments for episodic cardiovascular conditions such as PSVT and AFib. The company emphasizes innovation, teamwork, and integrity, aiming to develop impactful treatments while fostering a collaborative and value-driven environment.
Milestone Pharmaceuticals is a cardiovascular pharmaceutical company focused on developing and commercializing therapies for episodic cardiac rhythm disorders, including paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). Its lead product, CARDAMYST™ (etripamil nasal spray), is now available through retail pharmacies across the U.S. and has received regulatory approval in China, with ongoing Phase 3 clinical trials advancing etripamil for AFib-RVR. The company focuses on self-administered treatments that allow patients to manage acute cardiac episodes outside of emergency or healthcare settings.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Milestone Pharmaceuticals.
17% below the average for this role
Director, Technical Operations
Travere Therapeutics
Registered Nurse - Atrial Fibrillation Clinic, Riverside Methodist Hospital
OhioHealth
Project Support Coordinator
Alfa Laval Thermal Co
Director, Analytical Chemistry - Peptides
Eli Lilly and Company
Electrophysiologist | Build a New EP Program | Private Practice | Partnership Track
Saint Mary of Nazareth
Director, Regulatory Affairs (Early Development)
USAJOBS